AMGN Stock Overview
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 2/6 |
| Dividends | 5/6 |
Amgen Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$269.64 |
| 52 Week High | US$288.46 |
| 52 Week Low | US$211.71 |
| Beta | 0.58 |
| 1 Month Change | 5.45% |
| 3 Month Change | 5.04% |
| 1 Year Change | -5.70% |
| 3 Year Change | 18.83% |
| 5 Year Change | 35.49% |
| Change since IPO | 25,031.49% |
Recent News & Updates
Recent updates
Are Investors Undervaluing Amgen Inc. (NASDAQ:AMGN) By 46%?
Oct 23
Is Amgen (NASDAQ:AMGN) Using Too Much Debt?
Sep 22Do Amgen's (NASDAQ:AMGN) Earnings Warrant Your Attention?
Sep 04Amgen (NASDAQ:AMGN) Is Increasing Its Dividend To $2.13
Aug 05Amgen Inc. (NASDAQ:AMGN) Shares Could Be 45% Below Their Intrinsic Value Estimate
May 30Amgen (NASDAQ:AMGN) Is Paying Out A Larger Dividend Than Last Year
May 09These 4 Measures Indicate That Amgen (NASDAQ:AMGN) Is Using Debt Reasonably Well
Apr 29Amgen (NASDAQ:AMGN) Is Increasing Its Dividend To $2.13
Apr 05Amgen Inc. (NASDAQ:AMGN) Shares Could Be 37% Below Their Intrinsic Value Estimate
Feb 27Amgen (NASDAQ:AMGN) Has Announced That It Will Be Increasing Its Dividend To $2.13
Feb 02Amgen's (NASDAQ:AMGN) Upcoming Dividend Will Be Larger Than Last Year's
Jan 19Amgen's (NASDAQ:AMGN) Dividend Will Be Increased To $2.13
Jan 03Shareholder Returns
| AMGN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 1.9% | 2.3% | 0.5% |
| 1Y | -5.7% | -7.9% | 11.0% |
Return vs Industry: AMGN exceeded the US Biotechs industry which returned -7.9% over the past year.
Return vs Market: AMGN underperformed the US Market which returned 11% over the past year.
Price Volatility
| AMGN volatility | |
|---|---|
| AMGN Average Weekly Movement | 3.2% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 15.4% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: AMGN is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: AMGN's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1980 | 25,200 | Bob Bradway | https://www.amgen.com |
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company’s products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.
Amgen Inc. Fundamentals Summary
| AMGN fundamental statistics | |
|---|---|
| Market Cap | US$142.68b |
| Earnings (TTM) | US$7.57b |
| Revenue (TTM) | US$26.83b |
19.1x
P/E Ratio5.4x
P/S RatioIs AMGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AMGN income statement (TTM) | |
|---|---|
| Revenue | US$26.83b |
| Cost of Revenue | US$7.05b |
| Gross Profit | US$19.78b |
| Other Expenses | US$12.22b |
| Earnings | US$7.57b |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 14.14 |
| Gross Margin | 73.73% |
| Net Profit Margin | 28.20% |
| Debt/Equity Ratio | 789.8% |
How did AMGN perform over the long term?
See historical performance and comparison